Investors have pinned their hopes on Leqembi as the U.S drugmaker's money spinner multiple sclerosis and spinal muscular atrophy (SMA) treatments face fierce competition from cheaper versions and rival drugs.
from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/sPEKhWa
Home »
Information and Updates: ET HealthWorld : ETHealthworld.com
,
Top Health News | Latest Healthcare Sector & Healthcare Industry news
» Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace
https://ift.tt/u1l3xjh
No comments:
Post a Comment